Multiple Myeloma Clinical Trials

$NCT06158841: Phase 3: Intravenous (IV) ABBV-383 Monotherapy Versus Standard Therapies Relapsed/Refractory Myeloma$

NCT06158841: Phase 3: Intravenous (IV) ABBV-383 Monotherapy Versus Standard Therapies Relapsed/Refractory Myeloma

NCT06158841: Phase 3: Intravenous (IV) ABBV-383 Monotherapy Versus Standard Therapies RRMM Study Assessing Activity of Intravenous (IV)...

NCT05558319: Phase 3: (GEM21menos65) Extended VRD Plus vs Isa-VRD vs Isa-V-Iberdomide - NDMM - ASCT

(GEM21menos65) (Isatuximab-VRD + ASCT) - (VRD extended + ASCT plus ERI) - (Isatuximab-VID + ASCT). ERI=Early Rescue Intervention...

NCT05272826: Phase 2: Study of Iberdomide, Bortezomib, and Dexamethasone for ND-NTE MM Patients

BOREALIS Trial - CMRG 010 NCT05272826: Phase 2: Study of Iberdomide, Bortezomib, and Dexamethasone for ND-NTE MM Patients Study of...

NCT04541368: Phase 1: A Study of CS1-targeted CAR-T Cells Therapy for RRMM After BCMA CAR-T Thaerapy

NCT04541368: Phase 1: A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy A Study of...